Retinoic Acid Receptors Rars Agonist Pipeline Insight
DelveInsight’s, “Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Retinoic Acid Receptor (RARs) Agonist Understanding
Retinoic Acid Receptor (RARs) Agonist: Overview
Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RARα, RARβ, and RARγ) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into mRNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of leads against breast, lung and prostate cancer or leukemia.
The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.
Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters
This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinoic Acid Receptor (RARs) Agonist Emerging Drugs
Palovarotene: Clementia Pharmaceuticals (Ipsen)
Palovarotene is a RARγ agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.
IRX 5183: Allergan (AbbVie)
IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RARα) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.
Further product details are provided in the report……..
Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Retinoic Acid Receptor (RARs) Agonist
There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.
Retinoic Acid Receptor (RARs) Agonist Report Insights
- Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Retinoic Acid Receptor (RARs) Agonist Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Retinoic Acid Receptor (RARs) Agonist drugs?
- How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?